Alpaca single B cell interrogation and heavy-chain-only antibody discovery on an optofluidic platform
Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
Accelerated antibody discovery targeting the SARS-CoV-2 spike protein for COVID-19 therapeutic potential
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
High-throughput optofluidic screening for improved microbial cell factories via real-time micron-scale productivity monitoring